Literature DB >> 21078116

Efficient and targeted delivery of siRNA in vivo.

Min Suk Shim1, Young Jik Kwon.   

Abstract

RNA interference (RNAi) has been regarded as a revolutionary tool for manipulating target biological processes as well as an emerging and promising therapeutic strategy. In contrast to the tangible and obvious effectiveness of RNAi in vitro, silencing target gene expression in vivo using small interfering RNA (siRNA) has been a very challenging task due to multiscale barriers, including rapid excretion, low stability in blood serum, nonspecific accumulation in tissues, poor cellular uptake and inefficient intracellular release. This minireview introduces major challenges in achieving efficient siRNA delivery in vivo and discusses recent advances in overcoming them using chemically modified siRNA, viral siRNA vectors and nonviral siRNA carriers. Enhanced specificity and efficiency of RNAi in vivo via selective accumulations in desired tissues, specific binding to target cells and facilitated intracellular trafficking are also commonly attempted utilizing targeting moieties, cell-penetrating peptides, fusogenic peptides and stimuli-responsive polymers. Overall, the crucial roles of the interdisciplinary approaches to optimizing RNAi in vivo, by efficiently and specifically delivering siRNA to target tissues and cells, are highlighted.
© 2010 The Authors Journal compilation © 2010 FEBS.

Mesh:

Substances:

Year:  2010        PMID: 21078116     DOI: 10.1111/j.1742-4658.2010.07904.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  95 in total

1.  Molecular Validation of PACE4 as a Target in Prostate Cancer.

Authors:  François D'Anjou; Sophie Routhier; Jean-Pierre Perreault; Alain Latil; David Bonnel; Isabelle Fournier; Michel Salzet; Robert Day
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

2.  In vivo RNA interference of a gonad-specific transforming growth factor-β in the Pacific oyster Crassostrea gigas.

Authors:  Arnaud Huvet; Elodie Fleury; Charlotte Corporeau; Virgile Quillien; Jean Yves Daniel; Guillaume Riviere; Pierre Boudry; Caroline Fabioux
Journal:  Mar Biotechnol (NY)       Date:  2011-12-07       Impact factor: 3.619

3.  Interaction of nucleic acids with the glycocalyx.

Authors:  Michael J Palte; Ronald T Raines
Journal:  J Am Chem Soc       Date:  2012-03-29       Impact factor: 15.419

Review 4.  Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.

Authors:  Saurabh Singh; Ajit S Narang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-10-28       Impact factor: 4.200

Review 5.  Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles.

Authors:  José M Morachis; Enas A Mahmoud; Adah Almutairi
Journal:  Pharmacol Rev       Date:  2012-04-27       Impact factor: 25.468

Review 6.  Designing highly active siRNAs for therapeutic applications.

Authors:  S Patrick Walton; Ming Wu; Joseph A Gredell; Christina Chan
Journal:  FEBS J       Date:  2010-12       Impact factor: 5.542

7.  In vitro-in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery.

Authors:  Kathryn A Whitehead; Jonathan Matthews; Philip H Chang; Farnaz Niroui; J Robert Dorkin; Mariano Severgnini; Daniel G Anderson
Journal:  ACS Nano       Date:  2012-07-06       Impact factor: 15.881

Review 8.  Nanoparticles targeting HLA-G for gene therapy in cancer.

Authors:  Ines Zidi; Nidhal Ben Amor
Journal:  Med Oncol       Date:  2011-04-17       Impact factor: 3.064

9.  Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape.

Authors:  Jerome Gilleron; William Querbes; Anja Zeigerer; Anna Borodovsky; Giovanni Marsico; Undine Schubert; Kevin Manygoats; Sarah Seifert; Cordula Andree; Martin Stöter; Hila Epstein-Barash; Ligang Zhang; Victor Koteliansky; Kevin Fitzgerald; Eugenio Fava; Marc Bickle; Yannis Kalaidzidis; Akin Akinc; Martin Maier; Marino Zerial
Journal:  Nat Biotechnol       Date:  2013-06-23       Impact factor: 54.908

Review 10.  Targeting long non-coding RNA to therapeutically upregulate gene expression.

Authors:  Claes Wahlestedt
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.